SCHEMBL3709552

SCHEMBL3709552

O=C(O)C1CC(N(Cc2ccccc2)Cc2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
DPP8 Q6V1X1 1/20 0.47
DPP7 Q9UHL4 1/20 0.47
YTHDC1 Q96MU7 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
S1PR1 P21453 1/20 0.41
S1PR5 Q9H228 1/20 0.41
MAOA P21397 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
OPRM1 P35372 1/20 0.40
CTSD P07339 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1536135 0.88 MEN1 (0.51) MEN1KMT2ADPP8DPP7YTHDC1
SCHEMBL19583110 0.87 MEN1 (0.46) MEN1KMT2ADPP8DPP7YTHDC1
SCHEMBL19583111 0.87 MEN1 (0.46) MEN1KMT2ADPP8DPP7YTHDC1
SCHEMBL13902931 0.87 MEN1 (0.46) MEN1KMT2ADPP8DPP7YTHDC1
SCHEMBL2991006 0.87 MEN1 (0.46) MEN1KMT2ADPP8DPP7YTHDC1
SCHEMBL19734564 0.86 KMT2A (0.45) MEN1KMT2ADPP8DPP7YTHDC1
SCHEMBL1934571 0.84 MEN1 (0.54) MEN1KMT2ADPP8DPP7YTHDC1
SCHEMBL12282446 0.84 MEN1 (0.54) MEN1KMT2ADPP8DPP7YTHDC1
SCHEMBL2994780 0.83 KMT2A (0.46) MEN1KMT2ADPP8DPP7MAOA
SCHEMBL2994779 0.83 KMT2A (0.46) MEN1KMT2ADPP8DPP7MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091438-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS MERCK SHARP & DOHME LLC (US) 2023-05-25 WO disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed
CN-110709402-B Heteroaryl pyrimidone derivatives, preparation method and medical application thereof 浙江海正药业股份有限公司 2022-05-10 CN disclosed
CN-110709402-A Heteroaryl pyrimidone derivatives, preparation method and medical application thereof 浙江海正药业股份有限公司 2020-01-17 CN disclosed
CN-109988120-A A kind of indoles amine -2,3- dioxygenase inhibitor and its preparation method and application 成都海创药业有限公司 2019-07-09 CN disclosed
EP-2209771-A1 CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES Pfizer, Inc. (US) 2010-07-28 EP disclosed
WO-2009060278-A1 CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES PFIZER INC. (US) 2009-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TCOF1, SLC10A2, PAM MEN1 77/4885KMT2A 2833/4885DPP8 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.